BlackRock Health Sciences Term Trust is a closed-end fund (NYSE: BMEZ) specializing in healthcare and biotech stocks, holding $1.69 billion under management. The fund employs call-writing overlay and invests in venture companies, expecting illiquidity premium. Currently trading at a 17.52% discount to NAV, it potentially offers a 21% upside over 8 years. Hedge fund Saba Capital’s increased interest adds another level of potential returns. But risks such as the widening discount and significant wait time for discount closure pose challenges.












